Table 1.
Patient | Anti-IFN-α2 auto-Abs (10 ng/ml) | Anti-IFN-β auto-Abs (10 ng/ml) | Anti-IFN-ω auto-Abs (10 ng/ml) | Anti-IFN-α2 auto-Abs (100 pg/ml) | Anti-IFN-ω auto-Abs (100 pg/ml) |
---|---|---|---|---|---|
P1 | 1 | 0 | 0 | 1 | 0 |
P2 | 1 | 1 | 1 | 1 | 1 |
P3 | 0 | 0 | 0 | 1 | 0 |
P4 | 0 | 0 | 0 | 0 | 1 |
P5 | 0 | 0 | 0 | 0 | 1 |
P6 | 0 | 0 | 0 | 0 | 1 |
P7 | 0 | 0 | 0 | 1 | 1 |
P8 | 1 | 0 | 1 | 1 | 1 |
P9 | 1 | 0 | 1 | 1 | 1 |
P10 | 0 | 0 | 0 | 1 | 0 |
P11 | 0 | 0 | 0 | 1 | 1 |
P12 | 1 | 0 | 0 | 1 | 1 |
P13 | 0 | 0 | 0 | 0 | 1 |
P14 | 1 | 1 | 1 | 1 | 1 |
P15 | 0 | 0 | 0 | 0 | 1 |
P16 | 0 | 0 | 1 | 0 | 1 |
P17 | 0 | 0 | 0 | 0 | 1 |
P18 | 0 | 0 | 0 | 0 | 1 |
P19 | 0 | 0 | 0 | 0 | 1 |
1: neutralizing. 0: non-neutralizing.